uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results, Misses Expectations By $0.40 EPS

uniQure (NASDAQ:QURE) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40), FiscalAI reports. The company had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.45 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. During the same quarter last year, the company earned ($0.69) earnings per share.

Here are the key takeaways from uniQure’s conference call:

• AMT-130 remains on track for a U.S. BLA submission in the third quarter under the FDA’s Accelerated Approval pathway, with three-year Phase I/II data accepted as the primary basis. A U.K. submission to the MHRA is also planned for the third quarter.
• The FDA indicated that a confirmatory study may use a randomized standard-of-care control rather than a sham procedure, potentially simplifying execution. uniQure expects to align on the design and begin a global study promptly, with Total Functional Capacity at 36 months under consideration as the primary endpoint.
• uniQure expects to present four-year AMT-130 data in September, including safety, tolerability, functional outcomes, natural-history comparisons and CSF neurofilament light data. Management is in a quiet period and declined to provide additional commentary on the results ahead of the readout.
• Early AMT-260 epilepsy data showed seizure reductions of 79% to 100% below baseline in three of six low-dose patients, but outcomes varied widely among the remaining participants; higher-dose enrollment is nearly complete. AMT-191 produced dose-dependent enzyme activity increases in all 11 patients, although two grade 3 liver-enzyme events paused further mid- and high-dose dosing pending FDA agreement on monitoring.
• Cash, cash equivalents and investments totaled $810.3 million at quarter-end, up from $622.5 million at year-end 2025, and management expects the balance sheet to fund operations, the confirmatory trial, potential AMT-130 launches and ongoing development into 2030.

uniQure Price Performance

Shares of QURE traded up $3.23 during trading hours on Wednesday, hitting $39.89. 939,928 shares of the company were exchanged, compared to its average volume of 2,561,806. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The company has a market capitalization of $2.52 billion, a PE ratio of -11.47 and a beta of 0.90. The firm has a fifty day simple moving average of $36.44 and a 200-day simple moving average of $25.89. uniQure has a one year low of $8.73 and a one year high of $71.50.

Analysts Set New Price Targets

QURE has been the topic of a number of recent analyst reports. Royal Bank Of Canada upped their target price on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. The Goldman Sachs Group boosted their price objective on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, June 18th. Stifel Nicolaus set a $28.00 price objective on uniQure in a research note on Tuesday, May 5th. Chardan Capital increased their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Finally, Leerink Partners increased their target price on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $64.17.

Insider Buying and Selling

In other news, Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the completion of the sale, the director directly owned 43,254 shares of the company’s stock, valued at $1,949,025.24. This represents a 21.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total value of $982,995.48. Following the completion of the transaction, the director owned 25,996 shares of the company’s stock, valued at $1,207,254.24. This trade represents a 44.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 433,229 shares of company stock valued at $17,944,799 over the last ninety days. 4.65% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Woodline Partners LP raised its holdings in shares of uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after acquiring an additional 35,175 shares during the period. Legal & General Group Plc purchased a new position in uniQure during the 2nd quarter worth approximately $497,000. Marshall Wace LLP raised its stake in uniQure by 276.5% during the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after purchasing an additional 163,749 shares during the period. California State Teachers Retirement System purchased a new stake in shares of uniQure in the second quarter valued at $540,000. Finally, Ameriprise Financial Inc. boosted its position in shares of uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after buying an additional 212,218 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.